NASDAQ:SLNO - Soleno Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 361.54 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.95
▼ -0.04 (-2.01%)
1 month | 3 months | 12 months
Get New Soleno Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLNO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLNO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.00
▲ +361.54% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Soleno Therapeutics in the last 3 months. The average price target is $9.00, with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 361.54% upside from the last price of $1.95.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Soleno Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/29/2020GuggenheimInitiated CoverageBuy$8.00High
i
6/5/2020LaidlawReiterated RatingBuy$10.00Low
i
Rating by Yale Jen at Laidlaw
1/10/2020Craig HallumInitiated CoverageBuy$8.00High
i
12/23/2019LaidlawInitiated CoverageBuyHigh
i
Rating by Francois Brisebois at Laidlaw
12/23/2019OppenheimerInitiated CoverageOutperform$10.00High
i
7/8/2019LaidlawInitiated CoverageBuy$10.00High
i
12/20/2018Maxim GroupSet Price TargetBuy$5.00Low
i
Rating by Jason Kolbert at Maxim Group
11/16/2018Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Caroline Palomeque at Maxim Group
10/8/2018Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Caroline Palomeque at Maxim Group
9/17/2018Maxim GroupReiterated RatingBuy$4.00Low
i
Rating by Caroline Palomeque at Maxim Group
8/15/2018Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Caroline Palomeque at Maxim Group
7/30/2018Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Caroline Palomeque at Maxim Group
6/22/2018Roth CapitalInitiated CoverageBuy$14.00High
i
Rating by Y. Rahimi at Roth Capital
5/16/2018Maxim GroupSet Price TargetBuy$4.00Medium
i
Rating by Caroline Palomeque at Maxim Group
5/16/2018Noble FinancialSet Price TargetBuy$4.00Low
i
Rating by Caroline Palomeque at Noble Financial
4/2/2018Maxim GroupSet Price TargetBuy$4.00High
i
Rating by Jason McCarthy at Maxim Group
2/13/2018Maxim GroupSet Price TargetBuy ➝ Buy$8.00 ➝ $4.00Low
i
Rating by Jason Kolbert at Maxim Group
12/8/2017Maxim GroupSet Price TargetBuy$8.00Low
i
Rating by Jason Kolbert at Maxim Group
10/12/2017Maxim GroupSet Price TargetBuy$25.00N/A
i
Rating by Jason Kolbert at Maxim Group
9/13/2017Maxim GroupReiterated RatingBuy$25.00Medium
i
Rating by Jason Kolbert at Maxim Group
8/14/2017Maxim GroupSet Price TargetBuy$25.00High
i
Rating by Jason Kolbert at Maxim Group
7/5/2017Maxim GroupSet Price TargetBuy$25.00Medium
i
Rating by Jason Kolbert at Maxim Group
5/4/2017Maxim GroupSet Price TargetBuy$25.00High
i
Rating by Jason McCarthy at Maxim Group
3/11/2017Maxim GroupSet Price TargetBuy$25.00Low
i
Rating by Jason McCarthy at Maxim Group
1/26/2017Maxim GroupUpgradeHold ➝ Buy$25.00N/A
i
Rating by Jason Kolbert at Maxim Group
11/23/2016Maxim GroupDowngradeBuy ➝ HoldN/A
i
Rating by Jason Kolbert at Maxim Group
6/15/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Benji Star at Maxim Group
6/8/2016Maxim GroupReiterated RatingBuy$15.00N/A
i
Rating by Sharon Stein at Maxim Group
5/10/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
2/26/2016Maxim GroupReiterated RatingBuy$15.00N/A
i
Rating by Jason Kolbert at Maxim Group
1/27/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
1/20/2016Maxim GroupReiterated RatingBuy$15.00N/A
i
Rating by Jason Kolbert at Maxim Group
12/28/2015Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
12/21/2015Maxim GroupReiterated RatingBuy$45.00 ➝ $15.00N/A
i
(Data available from 11/23/2015 forward)
Soleno Therapeutics logo
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $1.95
$1.94
$2.00

50 Day Range

MA: $1.93
$1.61
$2.10

52 Week Range

Now: $1.95
$1.30
$4.39

Volume

209,981 shs

Average Volume

538,736 shs

Market Capitalization

$155.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45